Marijuana and the FDA: A not-so-merry-go-around

3 October 2016

By Dr Nicola Davies

In response to a sharp increase in the number of patients now looking for treatment outside of FDA-approved circles, the US Food and Drug Administration has been keen to remind the public that it has a reasonable motive behind this stance, writes DR Nicola Davies in her monthly exclusive FDA Blog for The Pharma Letter.

The agency publicly states on its website that it “understands that caregivers and patients are looking for treatment options for unmet medical needs.” However, the FDA holds firm in its resolve to keep cannabis and marijuana-derived medical treatments at bay. As of now, the most recent petition to upgrade cannabis from a Schedule 1 drug classification has been denied. On a scale of one to five, a higher number represents more potential for medical treatment and a lack of potential for abuse.

Why the reminder?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK